DSIP

Delta sleep-inducing peptide explored for sleep modulation, endocrine effects and stress-related signalling, with heterogeneous human data.

Evidence: Mixed Human / Preclinical Function: Sleep & Neuroendocrine Modulation Class: Neuropeptide (nonapeptide)

Explore calculators for this peptide

Use the Peptide Research Tools to experiment with reconstitution, mg/kg ranges and simplified half-life curves for DSIP. All values are placeholders and must be aligned with your own research protocol.

Open DSIP in calculators →

Research frame & potential applications

DSIP (delta sleep-inducing peptide) is a small neuropeptide originally identified in cerebral venous blood during slow‑wave sleep and studied as a candidate sleep‑regulating factor. Work in animals and humans suggests it can influence slow‑wave activity, total sleep time and stress‑linked endocrine axes, but its native role, receptors and clinical utility remain only partially defined.

Research areas & putative benefits

How DSIP is being explored in experimental and clinical contexts – framed as mechanistic signals, not treatment claims.

Modulation of sleep architecture in animals and humans, with reports of increased slow‑wave sleep and total sleep time after DSIP or analogues in some studies.
Influence on stress axes and endocrine parameters, including changes in ACTH, cortisol, growth hormone and luteinizing hormone in experimental settings.
Exploratory use in chronic insomnia, stress‑related states and substance‑withdrawal paradigms, where DSIP has been studied for sleep and anxiety support.
Neurophysiological interest around pain perception, seizure thresholds and sensory gating, linked to interactions with GABAergic, glutamatergic and opioid systems.

Mechanism stack

Proposed pathways through which DSIP and its analogues may influence sleep, stress and neuroendocrine regulation.

Sleep regulation

Slow-wave & delta activity

DSIP and DSIP‑like analogues can increase slow‑wave and delta EEG activity in several species when administered centrally or systemically, supporting a role in sleep initiation and consolidation in some models.

Endocrine axes

ACTH, cortisol, GH & LH

Experimental work indicates that DSIP can reduce basal corticotropin levels, influence cortisol output, stimulate growth hormone–releasing pathways and affect luteinizing hormone release, linking it to stress and anabolic signalling.

Neurotransmission

GABA / NMDA / opioid systems

DSIP appears to potentiate GABAergic effects, dampen NMDA receptor activity and interact indirectly with opioid pathways, which may contribute to its reported sedative, antinociceptive and anticonvulsant‑like properties in some paradigms.

Stress & circadian

Stress signalling & rhythms

Plasma DSIP‑like immunoreactivity follows a circadian pattern and responds to stress exposure in certain models, suggesting a modulatory role at the interface of sleep, stress and circadian regulation, even if the primary endogenous peptide remains elusive.

Evidence snapshot

Selected findings from animal sleep experiments, human insomnia work and mechanistic studies on DSIP.

Model / context	Observation	Notes
Animal sleep studies Preclinical sleep	Intracerebroventricular or systemic DSIP increased slow‑wave and delta sleep in rabbits, rats and cats in several experiments, though some protocols reported weaker or inconsistent effects.	Helped define DSIP as a candidate sleep‑modulating peptide but also highlighted sensitivity to dose, route, species and analogue used.
Human insomnia trials Clinical sleep	Small studies in chronic insomniacs reported modest increases in total sleep time and changes in sleep continuity with DSIP, while other work failed to show robust, reproducible benefits.	Overall evidence base is small and heterogeneous, limiting firm conclusions for insomnia treatment.
Endocrine & stress experiments Neuroendocrine	DSIP administration has been associated with altered ACTH and cortisol secretion, modulation of growth hormone and gonadotropin release, and changes in stress‑linked physiological responses.	Supports the framing of DSIP as a neuroendocrine modulator rather than a simple “sleep peptide”.
Mechanistic reviews Review	Reviews emphasize unresolved questions about the endogenous DSIP gene, receptor(s) and precise physiological function, despite the broad spectrum of observed biological activities.	DSIP is often described as a “still unresolved riddle” in sleep and neuropeptide research.

Risk frame & unknowns

Limitations and open questions when interpreting DSIP research.

Important research caveats

Evidence is mixed, with some positive sleep and stress findings but also negative or inconclusive trials, making overall effect size and reliability uncertain.
Endogenous DSIP biology (gene, receptors, native peptide forms) is not fully clarified, which complicates translation from analogues to physiology.
Long‑term safety, optimal dosing and interactions with other CNS‑active agents have not been studied in large, rigorous human cohorts.
Use outside controlled research contexts risks over‑interpreting early or inconsistent data, especially in vulnerable populations with sleep or psychiatric disorders.

This dossier summarizes mechanistic, preclinical and limited clinical findings on DSIP for scientific and educational purposes only. It does not provide medical advice, treatment guidance or dosing recommendations.